The US drugs regulator has approved the sale of a new nasal ... The spray was first approved by the Food and Drug Administration (FDA)'s advisory panel in February, and can cost up to $885 ...

Some also offer a newer, more expensive, nasal spray version ... health insurers that are willing to pay for some of the cost of ketamine therapy. But many patients pay some or all costs directly ...

Ketamine has a reputation as a party drug but is licensed as an anaesthetic. The study found use of the drug via a nasal spray led to "significant" improvements in depressive symptoms in the first ...

A watershed moment came in March when the U.S. Food and Drug Administration (FDA) approved Spravato, or esketamine, a ketamine nasal spray for adults with treatment-resistant major depression.